Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)

被引:4
|
作者
Kamiya, Koji [1 ]
Saeki, Hidehisa [2 ]
Tokura, Yoshiki [3 ,4 ]
Yoshihara, Shigemi [5 ]
Sugai, Junichi [6 ]
Ohtsuki, Mamitaro [1 ]
机构
[1] Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Nippon Med Sch, Dept Dermatol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
[3] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[4] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[5] Dokkyo Med Univ, Dept Pediat, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[6] Sugai Dermatol Parkside Clin, 6-7-7 Motoimaizumi, Utsunomiya, Tochigi 3210954, Japan
关键词
atopic dermatitis; pediatric; proactive therapy; rank-down therapy; topical corticosteroids; FLUTICASONE PROPIONATE CREAM; DOUBLE-BLIND; GUIDELINES; MANAGEMENT; RELAPSE; EMOLLIENT; CHILDREN; MODERATE; RISK; 0.05-PERCENT;
D O I
10.3390/jcm11216477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy, n = 24; rank-down therapy, n = 25). During maintenance treatment, the relapse rate was 8.33% in the proactive therapy group and 20.0% in the rank-down therapy group (p = 0.0859). The mean (+/- standard deviation) itching score on a numerical rating scale in the rank-down therapy group increased significantly from 2.5 +/- 1.9 to 3.6 +/- 2.6 (p = 0.0438). Adverse events occurred in 2 patients receiving proactive therapy and 3 patients receiving rank-down therapy. Proactive therapy appears to be as safe as rank-down therapy and may be more effective for itch in pediatric AD in remission.
引用
收藏
页数:11
相关论文
共 45 条
  • [31] Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial)
    Minami, Takuma
    Watanabe, Hirotoshi
    Kato, Takao
    Ikeda, Kaori
    Ueno, Kentaro
    Matsuyama, Ai
    Maeda, Junya
    Sakai, Yoji
    Harada, Hisako
    Kuriyama, Akira
    Yamaji, Kyohei
    Kitajima, Naoki
    Kamei, Jun
    Takatani, Yudai
    Sato, Yuki
    Yamashita, Yugo
    Mizota, Toshiyuki
    Ohtsuru, Shigeru
    BMC ANESTHESIOLOGY, 2023, 23 (01)
  • [32] Rationale and Design of a Randomized, Open-Label, Parallel-Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT-HT)
    Kario, Kazuomi
    Katsuya, Tomohiro
    Shimosawa, Tatsuo
    Taguchi, Takashi
    Tanabe, Ayumi
    Ohishi, Mitsuru
    JOURNAL OF CLINICAL HYPERTENSION, 2025, 27 (01)
  • [33] Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
    Nakagawa, Hidemi
    Nemoto, Osamu
    Igarashi, Atsuyuki
    Saeki, Hidehisa
    Kaino, Hironobu
    Nagata, Takeshi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 823 - 831
  • [34] Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study
    Di Fiorino, Mario
    Montagnani, Gino
    Trespi, Graziella
    Kasper, Siegfried
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (03) : 166 - 176
  • [35] Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    Rosenstock, Julio
    Raccah, Denis
    Koranyi, Laszlo
    Maffei, Laura
    Boka, Gabor
    Miossec, Patrick
    Gerich, John E.
    DIABETES CARE, 2013, 36 (10) : 2945 - 2951
  • [36] Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)
    Gonzalez-Lopez, Natalia
    Quintero, Enrique
    Gimeno-Garcia, Antonio Z.
    Bujanda, Luis
    Banales, Jesus
    Cubiella, Joaquin
    Salve-Bouzo, Maria
    Miguel Herrero-Rivas, Jesus
    Cid-Delgado, Estela
    Alvarez-Sanchez, Victoria
    Ledo-Rodriguez, Alejandro
    Luisa de-Castro-Parga, Maria
    Fernandez-Poceiro, Romina
    Sanroman-Alvarez, Luciano
    Santiago-Garcia, Jose
    Herreros-de-Tejada, Alberto
    Ocana-Bombardo, Teresa
    Balaguer, Francesc
    Rodriguez-Soler, Maria
    Jover, Rodrigo
    Ponce, Marta
    Alvarez-Urturi, Cristina
    Bessa, Xavier
    Roncales, Maria-Pilar
    Sopena, Federico
    Lanas, Angel
    Nicolas-Perez, David
    Adrian-de-Ganzo, Zaida
    Carrillo-Palau, Marta
    Gonzalez-Davila, Enrique
    PLOS MEDICINE, 2023, 20 (10)
  • [37] Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
    Kudo, Akihiro
    Machii, Noritaka
    Ono, Toshio
    Saito, Haruka
    Oshiro, Yoshito
    Takahashi, Ryu
    Oshiro, Koichi
    Taneda, Yoshinobu
    Higa, Moritake
    Nakachi, Ken
    Yagi, Shusuke
    Masuzaki, Hiroaki
    Sata, Masataka
    Shimabukuro, Michio
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (02)
  • [38] Effectiveness of Barnidipine 10 or 20 mg Plus Losartan 50-mg Combination Versus Losartan 100-mg Monotherapy in Patients With Essential Hypertension Not Controlled by Losartan 50-mg Monotherapy: A 12-Week, Multicenter, Randomized, Open-Label, Parallel-Group Study
    Parati, Gianfranco
    Giglio, Alessia
    Lonati, Laura
    Destro, Maurizio
    Ricci, Alessandra Rossi
    Cagnoni, Francesca
    Pini, Claudio
    Venco, Achille
    Maresca, Andrea Maria
    Monza, Michela
    Grandi, Anna Maria
    Omboni, Stefano
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1270 - 1284
  • [39] A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension
    Lee, Hae-Young
    Kim, Kwang-Il
    Ihm, Sang Hyun
    Rhee, Moo-Yong
    Sohn, Il Suk
    Park, Sungha
    Jeon, Eun-Seok
    Song, Jong-Min
    Pyun, Wook Bum
    Sung, Ki-Chul
    Kim, Moo Hyun
    Kim, Sang-Hyun
    Kim, Seok-Yeon
    Kim, Shin-Jae
    Kim, Eung Ju
    Shin, Jinho
    Lee, Sung Yun
    Chun, Kook-Jin
    Jeong, Jin-Ok
    Chae, Shung Chull
    Yoo, Ki Dong
    Choi, Young Jin
    Park, Yong Hwan
    Kim, Cheol-Ho
    CLINICAL THERAPEUTICS, 2021, 43 (10) : 1746 - 1756
  • [40] Fixed or Adjustable Maintenance-Dose Budesonide/Formoterol Compared with Fixed Maintenance-Dose Salmeterol/Fluticasone Propionate in Asthma Patients Aged ≥16 Years Post Hoc Analysis of a Randomized, Double-Blind/Open-Label Extension, Parallel-Group Study
    Aalbers, Rene
    CLINICAL DRUG INVESTIGATION, 2010, 30 (07) : 439 - 451